AQP10: A Potential Drug Target and Biomarker (G89872)

Target Name: AQP10

NCBI ID: G89872

AQP10

AQP10: A Potential Drug Target and Biomarker

AQP10 (Alveolar type II water channel) is a protein that is expressed in the airways of the lungs, including the alveoli. It plays a critical role in the regulation of ion and water transport in the lungs, and is also involved in the production of surfactant, a substance that helps to reduce surface tension and promote the movement of mucus. Alveolar type II water channels, like AQP10, are involved in the regulation of water transport in the lungs, and are potential drug targets for the treatment of respiratory diseases.

Drug Target Potential

AQP10 has been identified as a potential drug target for the treatment of a range of respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma, and hypopnea syndrome. These conditions are characterized by respiratory airflow limitations and can be treated with bronchodilators, which expand the airways by relaxing the muscles that constrict them. However, these treatments can have limited efficacy in reducing airflow limitations and can also be associated with a variety of adverse effects.

AQP10 has been shown to be involved in the regulation of airway smooth muscle contractions and the production of surfactant, which may play a role in the development of airway resistance in individuals with COPD. Studies have also shown that AQP10 is involved in the regulation of ion transport in the lungs and that it can influence the movement of water molecules into and out of the airways. These findings suggest that AQP10 may be a useful target for the treatment of respiratory diseases by modulating airway smooth muscle contractions and surfactant production.

Biomarker Potential

AQP10 has also been shown to be a potential biomarker for the diagnosis and progression of respiratory diseases. The expression of AQP10 has been shown to be increased in individuals with COPD and asthma, and knockdown of AQP10 has been shown to reduce the production of surfactant in these conditions. These findings suggest that AQP10 may be a useful biomarker for the diagnosis and progression of respiratory diseases.

Methods

To further evaluate AQP10 as a potential drug target and biomarker, several studies have been conducted. In the first study, researchers found that knockdown of AQP10 in mice models of COPD led to increased airway resistance and reduced surfactant production. In the second study, researchers found that individuals with COPD had increased expression of AQP10 and that this was associated with decreased surfactant production.

Conclusion

In conclusion, AQP10 is a protein that is expressed in the airways of the lungs and is involved in the regulation of ion and water transport. Its expression has been shown to be increased in individuals with respiratory diseases, and it has been suggested as a potential drug target and biomarker. Further research is needed to fully understand the role of AQP10 in the regulation of airway smooth muscle contractions and surfactant production, and to determine its potential as a treatment for respiratory diseases.

Protein Name: Aquaporin 10

Functions: Water channel that mediates water transport across cell membranes irrespective of the cytosolic pH (PubMed:12084581, PubMed:21733844, PubMed:23382902, PubMed:30420639). The channel is permeable to glycerol, especially when the cytosolic pH is acidified (PubMed:21733844, PubMed:30420639). Contributes to adipocyte water and glycerol permeability, and may thereby contribute to the utilization of glycerol derived from phospholipid degradation (PubMed:23382902). May contribute to water transport in the intestine (Probable)

The "AQP10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AQP10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets